Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

  • The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 to treat retinitis pigmentosa (RP).
  • ADX-2191 is a methotrexate for intravitreal injection.
  • Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
  • Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsOrphan Drug DesignationRetinitis Pigmentosa
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!